Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed. In this trial, we are evaluating efficacy of capecitabine in metastatic renal cell carcinoma patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kidney Cancer Research Bureau
• Treatments: Capecitabine

Criteria

Inclusion Criteria:

• histologically confirmed non-clear cell renal cell carcinoma

• confirmed metastatic sites

• no chemotherapy in history

Exclusion Criteria:

• metastases in CNS

• previous targeted therapy

• other tumor